SIRONA Trial Confirms Sirolimus-Coated Balloons as Superior Alternative for Femoropopliteal Disease

SIRONA Trial Results: A New Era in Femoropopliteal Disease Treatment

The latest data unveiled from the SIRONA trial, presented at TCT 2026 and published in JACC Cardiovascular Interventions, has provided significant insights into the treatment of femoropopliteal artery disease using sirolimus-coated balloons (SCB) compared to their paclitaxel-coated counterparts. The three-year results indicate a remarkable increase in freedom from clinically driven target lesion revascularization (cdTLR) for patients utilizing the MagicTouch PTA SCB, signifying a shift in standard practice for managing this prevalent condition.

The SIRONA Trial Overview

Conducted across 25 prominent centers spanning Germany and Austria, this investigator-initiated multicenter randomized trial enrolled 482 patients suffering from symptomatic femoropopliteal artery disease, predominantly with intermittent claudication (more than 96%). Post successful lesion predilation, participants were randomized either to receive the SCB or a paclitaxel-coated balloon (PCB) angioplasty. Previous results from the trial had already confirmed non-inferiority regarding patency and safety during the initial 12 months.

Prof. Ulf Teichgräber of Jena University Hospital, the principal investigator, presented these findings, marking a pioneering randomized comparison of these two technologies extending beyond the two-year mark.

Key Findings of the Study

The critical takeaway from the SIRONA trial results at the three-year checkpoint is the heightened rate of freedom from repeat procedures, with findings indicating that 88.2% of patients treated with the SCB remained free from cdTLR compared to 80.2% in the PCB group. The absolute difference noted was 8.0 percentage points (95% CI 1.0–14.8; P=0.01), with a hazard ratio of 0.60 signaling a promising advantage for the SCB treatment. This divergence in outcomes became evident after the first year of treatment, emphasizing the long-term benefits of SCB technology.

While both treatment groups demonstrated improvements in patient-reported walking distance and quality of life, these enhancements showed no significant variability between the two. Notable safety outcomes were also comparable, with all-cause mortality recorded at 7.4% across both treatment types, and major amputations being rare. For both SCB and PCB, amputation-free survival rates were impressively high at 92.1% and 92.2% respectively. Furthermore, freedom from clinically driven target vessel revascularization exhibited minimal discrepancy (83.8% for SCB vs 79.1% for PCB; P=0.27).

Implications and Future of Treatment

The groundbreaking findings emerge amidst growing concerns regarding the safety of paclitaxel-coated devices, fueled by investigations such as the SWEDEPAD 2 trial, which prompted a reevaluation of usage recommendations by the European Society for Vascular Surgery in treating claudication. Although the SIRONA trial primarily focused on its initial 12-month endpoints, the exploratory nature of the three-year analysis calls for further validation of the cdTLR advantage seen with SCB treatment. The research team plans to continue monitoring these outcomes over a five-year follow-up period, crucial for validating whether the apparent benefits of SCB will persist long-term.

Dr. Manish Doshi, founder and managing director of Concept Medical, expressed gratitude towards the SIRONA investigators and the patients involved, asserting that these results solidify the standing of MagicTouch PTA as a more effective approach. As a pioneering product, MagicTouch PTA employs proprietary Nanoluté technology to effectively deliver therapeutic sirolimus particles into vascular walls, showcasing not just efficacy but also the commitment of Concept Medical to ongoing rigorous data collection regarding drug delivery technologies in the realm of peripheral artery disease.

With the advent of these promising results, the medical community anticipates a paradigm shift in the treatment of femoropopliteal artery disease, moving towards technologies that offer not only improved efficacy but also enhanced patient outcomes.